BaiOS · The gates almost nobody sets up

Business planning for biotech startups.

BaiOS is your development plan in one place. Every gate carries what it costs to reach it. The money behind it is split into collected, committed, and not counted at all. That cost stays up to date as the plan moves.

Get started See how it worksOne living plan. Science, regulation and money, connected.

BaiOS overview: the pipeline and the financials of a venture in one screen

The problem

A brilliant asset, and no system to turn it into a company.

Early-stage biotech runs on scattered files and a founder wearing every hat. A spreadsheet does not know what a regulatory gate is. BaiOS does.

No operator on the plan

The founder runs science, funding and the board update alone, with no CFO, PMO or regulatory lead to hold it together.

Cash against unclear milestones

You know how many months of runway are left. You do not know which milestone unlocks the next round, or what it costs.

Four plans, four files

Science, regulatory, financial and investor stories live in separate documents with different assumptions.

Gates that are just tasks

The roadmap lists activities, not decision gates: no criteria, no dependencies, no go/no-go.

The plan dies in a PDF

The deck is rebuilt by hand every 18 months instead of falling out of a living model.

European funding is a maze

CDTI, ENISA, EIC, Eurostars, equity and loans, each with its own timing and eligible costs. All of it planned in disconnected spreadsheets.

Milestone-to-Money

How BaiOS connects the gate to the money.

The gate ↔ money relationship is the soul of the product. Change one assumption and the runway, the gates and the funding gap move with it.

Map the asset

One master record: company, asset, indication and a living target product profile. The plan is contextual, not a pretty agenda.

Sequence the gates

Decision gates, not tasks: each carries minimum criteria, evidence, cost, date, dependencies and a RAG status.

Price each milestone

Every milestone is linked to a cost and to the funding it unlocks. "What if the tox study slips six months?" is answered in seconds.

Track the runway

Burn-to-milestone and cash-out date, not vanity burn. A runway that knows what a gate is, recomputed server-side.

Development plan · illustrative

Toxicity study

Preclinical

€185K

▲ on track

PCT filing

Intellectual property

€32K

● pending

Scientific advice meeting

Regulatory · AEMPS

Mar '27

▼ 6 wks

Series A close

Investment

€2.4M

▲ 8% vs plan

The engine

Milestone to money, in one chain.

Anyone can tell a founder they have twelve months of cash. The useful sentence names the next milestone, what it costs and what unlocks it. Change one assumption and the runway, the gates and the funding gap all move with it.

The living plan

MilestoneGate criteria · Evidence

CostPrice per gate · Dependencies

RunwayBurn-to-milestone · Cash-out

FundingGrant · Bridge · Round

Inside BaiOS

The plan, as the founder actually sees it.

BaiOS financials: cash curve, runway metrics and the funding gap per milestone

BaiOS roadmap calendar with one lane per asset and dependency arrows

BaiOS funding map: a Sankey from each funding source through the gate it feeds to the milestone it pays for

The two areas

Two areas, one connected model.

R&D planning is what has to be proven. Financial planning is what it costs and who pays for it. Nothing here is independent: a change in the TPP moves the cost, the timeline, the risk and the story with it.

R&D planning

What has to be achieved, in what order, who runs it, and what proves it.

Company & Asset Profile

The master record that makes the software contextual, not just a pretty agenda.

Living TPP

A target product profile that is alive, not a dead PDF. It is the base of every assumption.

Development Roadmap

A scientific-regulatory roadmap with templates by modality.

Regulatory Gates

The differentiator: decision gates, not regulatory tasks.

Team, capacity & suppliers

Whether the team can actually run the plan, and the CROs and CDMOs it depends on.

Risk register & IP

Living risks with runway impact, and the patent families and exclusivity date the plan has to fit inside.

Financial planning

What it costs, where the money comes from, and what the investor is told.

Financial Plan & Runway

Beyond cash in, cash out: burn-to-milestone and cash-out date.

Milestone cost & funding gap

What each milestone costs, what is funded and what is still missing. Per milestone, not in a total.

Mixed Funding Planner

Equity, grants, loans and business development in one place. It is the European non-dilutive map that US tools ignore.

Scenario Planning

Every assumption automatically impacts cash, milestones and reporting.

Market model

Population, uptake and pricing. It is the revenue line the whole plan is aiming at.

Investor & Board Reporting

The investor and board figures, on one screen, reading from the live plan.

Positioning

What BaiOS is not.

Every alternative owns one slice of the problem. BaiOS ties gate ↔ money together, with European funding logic and Adbaio advisory built in. None of the others have that.

Not Asana with a lab coat

Task tools (Asana, Notion, Monday) have no biotech logic: no gates, no TPP, no runway that knows what a milestone is.

Not a pharma PPM

Planisware and Planview are a Boeing cockpit for a four-person spin-off.

Not an FP&A app

Runway and Pigment don't know what a clinical trial application package is, or which milestone unlocks a Series A.

Not regulatory AI

Weave Bio automates documents; it does not plan the company.

Not US-only

Orchestra Bio is the closest, but ignores European public funding and is not built for spin-offs.

BaiOS + Adbaio

The software keeps the plan alive. The advisor keeps it right.

Adbaio without BaiOS is a great plan that goes stale in a PDF. BaiOS without Adbaio is eighty empty fields a founder abandons. Together they are a living plan with expert judgement embedded in it. The software retains, the advisory reviews it monthly.

Pricing